Business
Soleno Therapeutics Announces Publication of Results from Previously Completed Phase II Trial of DCCR for Treatment of Prader-Willi Syndrome
Data Published for First Time in Peer-Reviewed Journal REDWOOD CITY, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ:
About this update from Soleno Therapeutics, Inc.
[{"type":"text","content":"Data Published for First Time in Peer-Reviewed Journal\nREDWOOD CITY, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the results of the previously completed Phase II trial of diazoxide chloride controlled release (DCCR) for the treatment of Prader-Willi Syndrome (PWS) have been published for the first time in a peer-reviewed journal. The data are available in the current online edition of PLOS One, a peer-reviewed open access scientific journal published by the Public Library of Science. The publication is available at https://doi.org/10.1371/journal.pone.0221615.\n “We are pleased that data from our Phase II trial of DCCR in PWS has been published in a prestigious peer-reviewed journal, PLOS One,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics. “Based on the results from this Phase II trial, we designed and initiated a Phase III clinical development program that includes DESTINY PWS. Importantly, enrollment remains on track for the availability of top-line data from DESTINY PWS in the first half of 2020.” About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, is currently being evaluated in a Phase III clinical development program.For more information, please visit www.soleno.life. Forward-Looking StatementsThis press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ability to complete enrollment of the Phase III C601 study in PWS during 2019 and receive top-line data in the first half of 2020. We may use terms such as \"believes,\" \"estimates,\" \"anticipates,\" \"expects,\" \"plans,\" \"intends,\" \"may,\" \"could,\" \"might,\" \"will,\" \"should,\" \"approximately\" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis fo...